What is the appropriate duration of proton pump inhibitor (PPI) therapy and tapering strategy for patients?

How Long Can We Put Patients on PPI

Most patients should receive PPIs for only 4-8 weeks unless they have a definitive indication for long-term use, and all patients on chronic PPIs should undergo regular review to determine if continued therapy remains appropriate. 1

Duration Based on Indication

The appropriate duration of PPI therapy depends entirely on the underlying indication:

Short-Term Use Only (≤8 weeks)

• Uncomplicated GERD/nonerosive reflux disease
• H. pylori eradication
• NSAID-related ulcer treatment
• Functional dyspepsia (initial trial)
• Eosinophilic esophagitis 1

Long-Term Use Justified (>8 weeks)

• Barrett's esophagus
• Severe erosive esophagitis (LA grade C/D)
• History of esophageal ulcer or peptic stricture
• Gastroprotection in high-risk patients on chronic aspirin/NSAIDs
• Secondary prevention of peptic ulcers
• Zollinger-Ellison syndrome 1

Conditional Long-Term Use

• PPI-responsive endoscopy-negative reflux disease with symptom recurrence upon cessation
• Esophageal strictures from GERD
• Idiopathic pulmonary fibrosis progression prevention 1

Mandatory Review Protocol

Every patient on a PPI requires regular documentation of ongoing indications, with primary care providers responsible for this review. 1 This is critical because:

• Without an ongoing indication, PPIs can only cause harm (pill burden, costs, potential adverse effects)
• Most PPIs are prescribed by primary care physicians who should lead de-prescribing efforts
• Many patients continue PPIs indefinitely without clear justification

For patients with unproven GERD on continued PPI therapy, evaluate appropriateness and dosing within 12 months of initiation. 2 Consider endoscopy with prolonged wireless reflux monitoring off PPI to establish whether long-term therapy is truly needed.

De-Prescribing Strategy

Who Should Be Considered for Discontinuation

All patients without a definitive indication for chronic PPI use should be considered for trial of de-prescribing. 1 This is particularly important because most GERD patients have nonerosive disease that doesn't require indefinite therapy.

Dose Reduction Before Discontinuation

Patients on twice-daily dosing should first be stepped down to once-daily PPI. 1 Double-dose PPIs (standard dose twice daily or double-strength once daily) are not FDA-approved and have been more strongly associated with complications including pneumonia, hip fracture, and C. difficile infection, though causality is not proven.

Tapering vs. Abrupt Discontinuation

Either tapering or abrupt discontinuation are reasonable approaches—the evidence shows comparable success rates. 1, 3 A 2026 randomized trial found no difference in successful discontinuation at 24 weeks (74.2% vs 75.0%) or 48 weeks between immediate discontinuation and gradual tapering 3. An earlier trial comparing abrupt discontinuation with 3-week tapering showed similar results (31% vs 22% remaining off PPIs at 6 months) 1.

However, the physiologic rationale for tapering exists: parietal cell hyperplasia may take 2-6 months to regress after PPI withdrawal, and the tapering regimens studied may have been too rapid 1.

Managing Rebound Acid Hypersecretion (RAHS)

Patients must be counseled that transient upper GI symptoms after discontinuation are common and do not necessarily indicate need for resuming continuous PPIs. 1 This rebound phenomenon can last up to 2 months but typically resolves.

Bridging Strategies During Withdrawal

• On-demand PPIs (use only when symptomatic)
• H2-receptor antagonists as needed
• Antacids for breakthrough symptoms 1

Severe persistent symptoms lasting more than 2 months after discontinuation may indicate a true ongoing indication for PPI therapy. 1

Critical Exceptions: Do NOT Discontinue

Patients with complicated GERD should generally not be considered for PPI discontinuation: 1

• History of severe erosive esophagitis
• Esophageal ulcer
• Peptic stricture
• Barrett's esophagus

Common Pitfalls to Avoid

1. Don't continue PPIs indefinitely without documented indication - This is the most common error in practice
2. Don't use concern about adverse events as the sole reason for discontinuation - The decision should be based on lack of indication, not fear of side effects 1
3. Don't dismiss post-discontinuation symptoms as treatment failure - RAHS is temporary and manageable with lower-potency options
4. Don't keep patients on twice-daily dosing long-term - Step down to once-daily first 1

Practical Algorithm

1. Document the original indication for PPI use
2. Determine if indication still exists using the tables above
3. If no ongoing indication: Attempt de-prescribing
4. If on twice-daily dosing: Step down to once-daily first
5. Choose discontinuation method: Either taper or abrupt stop (patient preference)
6. Counsel about RAHS: Expect temporary symptoms for up to 2 months
7. Provide rescue options: On-demand PPIs, H2RAs, or antacids
8. Reassess at 2 months: Persistent symptoms may indicate true ongoing need

The evidence strongly supports that most patients can successfully discontinue PPIs when there is no definitive indication for long-term use, with success rates of 14-75% across studies 4, 5. The key is proper patient selection, counseling, and management of withdrawal symptoms.